Clinical Trials for Other Solid Tumor

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with refractory or relapsed locally advanced or metastatic solid tumors, such as HNSCC, NSCLC, and ccRCC, evaluating the investigational drug ABBV-CLS-484, an orally bioavailable inhibitor of PTPN2 and PTPN1 that enhances immune responses, as monotherapy or in combination with PD-1 inhibitors or VEGFR TKIs.

ClinicalTrials.gov ID: NCT04777994

Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial involves patients with advanced solid tumors characterized by RET gene abnormalities, where TAS0953/HM06, a selective RET inhibitor targeting the RET receptor tyrosine kinase, is administered to evaluate safety, dosing, and treatment efficacy. Phase II specifically includes NSCLC patients with RET gene fusion, assessing both those previously treated with RET inhibitors and those who have exhausted existing therapies.

ClinicalTrials.gov ID: NCT04683250

Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adult patients with chemo-resistant non-small cell lung cancer, head and neck squamous cell carcinoma, cervical, and uterine cancers, who express the NEO-201 antigen, to evaluate the combination of NEO-201, a monoclonal antibody targeting specific cancer cell glycans, with pembrolizumab, to potentially overcome resistance to checkpoint inhibitors.

ClinicalTrials.gov ID: NCT03476681

A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets adult patients with advanced or metastatic solid tumors having RAS, NF1, or RAF mutations, evaluating DCC-3116, an oral ULK1/2 inhibitor that blocks autophagy, both as monotherapy and in combination with trametinib, binimetinib, or sotorasib.

ClinicalTrials.gov ID: NCT04892017

A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.

ClinicalTrials.gov ID: NCT04787042

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates VMD-928, a selective TrkA inhibitor, in adult patients with advanced solid tumors or lymphoma that are resistant to existing therapies, focusing on those with TrkA overexpression or NTRK1 gene fusion.

ClinicalTrials.gov ID: NCT03556228

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

Restricted enrollment

The trial has restricted enrollment. For instance, you may only be eligible to participate if you were enrolled in a specific prior trial.

HealthScout AI summary: This trial focuses on patients with BRAF V600 mutation-positive cancers who have previously shown clinical benefit from and are currently treated with the BRAF inhibitor dabrafenib, the MEK inhibitor trametinib, or their combination in a Novartis or GSK parent study, assessing the long-term safety of these treatments.

ClinicalTrials.gov ID: NCT03340506